TrialAmerican journal of hematology2019

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

Susan M O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.